Palatin Technologies (PTN) EBITDA (2010 - 2026)
Palatin Technologies' (PTN) quarterly EBITDA came in at -$1.6 million in Q1 2026, up 67.15% YoY from -$945837.6 in Q1 2025, and up 78.43% on a QoQ basis from -$7.3 million in Q4 2025.
Palatin Technologies (PTN) EBITDA (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of EBITDA data on file, last reported at -$1.6 million in Q1 2026.
- Quarterly EBITDA rose 67.15% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.5 million (up 72.3% YoY) and the FY2025 annual result came in at -$17.5 million, up 22.39% from the prior year.
- EBITDA climbed to -$1.6 million in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $4.7 million in Q3 2025 to a low of -$13.1 million in Q2 2022.
- A 5-year average of -$5.7 million and a median of -$7.3 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA tumbled 322.59% — and 2025, when it soared 160.03%.
- Tracing PTN's EBITDA over 5 years: stood at -$5.6 million in 2022, then jumped by 121.0% to $1.2 million in 2023, then plunged by 322.59% to -$2.6 million in 2024, then plunged by 180.65% to -$7.3 million in 2025, then jumped by 78.43% to -$1.6 million in 2026.
- The last three EBITDA figures came in at -$1.6 million (Q1 2026), -$7.3 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 133.12 Mn |
| 10 | Palatin Technologies | 39.40 Mn | 39.40 Mn | - | -1.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.58 Mn |
| Dec 31, 2025 | -7.33 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | -7.76 Mn |
| Jun 30, 2024 | -8.34 Mn |
| Mar 31, 2024 | -9.22 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | -6.11 Mn |
| Jun 30, 2023 | -10.82 Mn |
| Mar 31, 2023 | -7.30 Mn |
| Dec 31, 2022 | -5.59 Mn |
| Sep 30, 2022 | -8.75 Mn |
| Jun 30, 2022 | -13.10 Mn |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | -8.45 Mn |
| Sep 30, 2021 | -7.22 Mn |
| Jun 30, 2021 | -13.70 Mn |